<p>Inspire Investing LLC 在第三季度购买了 CytomX Therapeutics, Inc.（NASDAQ:CTMX - 免费报告）的新头寸，根据其最近向证券交易委员会提交的 13F 表格。该基金购买了 522,482 股生物技术公司的股票，价值约为 1,667,000 美元。Inspire Investing LLC 在最近一个季度末持有 CytomX Therapeutics 约 0.32% 的股份。</p>
<p>获取 <strong>CytomX Therapeutics</strong> 的提醒：</p>
<p>其他几家机构投资者和对冲基金最近也调整了对该股票的持有。Orbimed Advisors LLC 在第二季度购买了 CytomX Therapeutics 的新头寸，价值约为 19,208,000 美元。Commodore Capital LP 在第二季度购买了 CytomX Therapeutics 的新股份，价值约为 17,462,000 美元。Perceptive Advisors LLC 在第二季度购买了 CytomX Therapeutics 的新头寸，价值约为 15,876,000 美元。Vivo Capital LLC 在第二季度购买了 CytomX Therapeutics 的新头寸，价值约为 13,096,000 美元。最后，Franklin Resources Inc. 在第二季度购买了 CytomX Therapeutics 的新股份，价值约为 13,096,000 美元。目前，67.77% 的股票由机构投资者持有。</p>
<h2>分析师设定新目标价</h2>
<p>几位分析师对该公司进行了评论。HC Wainwright 在 11 月 11 日的研究报告中将 CytomX Therapeutics 的目标价从 5.00 美元上调至 10.00 美元，并给予该公司 &#34;买入&#34; 评级。Barclays 在 10 月 21 日的报告中将 CytomX Therapeutics 的目标价从 3.50 美元上调至 6.00 美元，并给予该公司 &#34;增持&#34; 评级。Wedbush 在 11 月 7 日的报告中重申了 &#34;跑赢大盘&#34; 评级，并对 CytomX Therapeutics 的股票设定了 6.00 美元的目标价。华尔街 Zen 在 11 月 8 日的研究报告中将 CytomX Therapeutics 的评级从 &#34;持有&#34; 下调至 &#34;卖出&#34;。最后，Cantor Fitzgerald 在 9 月 22 日的报告中开始覆盖 CytomX Therapeutics 的股票。他们对该股票设定了 &#34;增持&#34; 评级和 6.00 美元的目标价。六位股票研究分析师对该股票给予了买入评级，一位分析师给予了持有评级。根据 MarketBeat，该公司的平均评级为 &#34;适度买入&#34;，共识目标价为 6.67 美元。</p>
<p><strong>查看我们对 CTMX 的最新分析</strong></p>
<h2>CytomX Therapeutics 股票上涨 5.6%</h2>
<p>NASDAQ CTMX 周五开盘价为 4.44 美元。该公司的 50 日移动平均价格为 3.89 美元，200 日移动平均价格为 2.93 美元。CytomX Therapeutics, Inc. 的 52 周低点为 0.40 美元，52 周高点为 4.62 美元。该公司的市值为 7.5142 亿美元，市盈率为 11.09，贝塔值为 2.37。</p>
<p>CytomX Therapeutics（NASDAQ:CTMX - 获取免费报告）最近于 11 月 6 日公布了其财报。这家生物技术公司报告的每股收益（EPS）为（0.09）美元，低于市场共识预期的（0.04）美元，差距为（0.05）美元。CytomX Therapeutics 的净利润率为 24.66%，股本回报率为 44.49%。该公司在本季度的收入为 596 万美元，而市场共识预期为 1150 万美元。整体来看，股票研究分析师预计 CytomX Therapeutics, Inc. 本年度将发布 -0.05 的每股收益。</p>
<h2>关于 CytomX Therapeutics</h2>
<p>（免费报告）</p>
<p>CytomX Therapeutics, Inc. 是一家临床阶段的生物制药公司，专注于基于其专有的 Probody® 平台发现和开发下一代治疗药物。该公司设计了在健康组织中保持不活跃但在肿瘤微环境中选择性激活的掩蔽抗体前药。这种方法旨在增强抗体基础疗法的安全性和耐受性，特别是针对免疫肿瘤学通路的疗法。</p>
<p>CytomX 的管线核心是 Pacmilimab (CX-072)，这是一种抗 PD-L1 Probody 治疗药物，目前正在针对多种实体瘤适应症进行临床评估。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票超过 CytomX Therapeutics</li>
<li>将你的 &#34;死钱&#34; 转变为每月 306 美元以上（从这个月开始）</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>华盛顿为战争做准备</li>
<li>在 1 月 1 日之前将 1,000 美元投入这只股票 [不是 NVDA]</li>
<li>麦当劳的秘密</li>
</ul>
<p><strong>想看看其他对冲基金持有的 CTMX 吗？</strong> 访问 HoldingsChannel.com 获取 CytomX Therapeutics, Inc.（NASDAQ:CTMX - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1RNWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1RNWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 CytomX Therapeutics 吗？</h2>
<p>在你考虑 CytomX Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前... 而 CytomX Therapeutics 并不在名单上。</p>
<p>虽然 CytomX Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CytomX治疗

<p>Inspire Investing LLC 在第三季度收购了 522,482 股 CytomX Therapeutics，价值 1,667,000 美元。该收购在向 SEC 提交的 13F 表格中进行了报告。分析师们为 CytomX 设置了新的目标价格，其中 HC Wainwright 将目标提高至 10.00 美元，巴克莱则设定为 6.00 美元。该股票的评级为 “适度买入”，共识目标价格为 6.67 美元。CytomX 的股价上涨了 5.6%，周五开盘价为 4.44 美元</p>

<p>Inspire Investing LLC bought a new position in CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The fund bought 522,482 shares of the biotechnology company's stock, valued at approximately $1,667,000. Inspire Investing LLC owned approximately 0.32% of CytomX Therapeutics at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Inspire Investing LLC 在第三季度购买了 CytomX Therapeutics, Inc.（NASDAQ:CTMX - 免费报告）的新头寸，根据其最近向证券交易委员会提交的 13F 表格。该基金购买了 522,482 股生物技术公司的股票，价值约为 1,667,000 美元。Inspire Investing LLC 在最近一个季度末持有 CytomX Therapeutics 约 0.32% 的股份。</p>
</div><p>Get <strong>CytomX Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>CytomX Therapeutics</strong> 的提醒：</p>
</div><p>Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Orbimed Advisors LLC bought a new position in CytomX Therapeutics in the 2nd quarter worth about $19,208,000. Commodore Capital LP bought a new stake in CytomX Therapeutics during the 2nd quarter valued at about $17,462,000. Perceptive Advisors LLC purchased a new position in CytomX Therapeutics in the second quarter worth about $15,876,000. Vivo Capital LLC bought a new position in shares of CytomX Therapeutics in the second quarter worth approximately $13,096,000. Finally, Franklin Resources Inc. purchased a new stake in shares of CytomX Therapeutics during the second quarter valued at approximately $13,096,000. 67.77% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金最近也调整了对该股票的持有。Orbimed Advisors LLC 在第二季度购买了 CytomX Therapeutics 的新头寸，价值约为 19,208,000 美元。Commodore Capital LP 在第二季度购买了 CytomX Therapeutics 的新股份，价值约为 17,462,000 美元。Perceptive Advisors LLC 在第二季度购买了 CytomX Therapeutics 的新头寸，价值约为 15,876,000 美元。Vivo Capital LLC 在第二季度购买了 CytomX Therapeutics 的新头寸，价值约为 13,096,000 美元。最后，Franklin Resources Inc. 在第二季度购买了 CytomX Therapeutics 的新股份，价值约为 13,096,000 美元。目前，67.77% 的股票由机构投资者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several analysts have commented on the company. HC Wainwright increased their target price on CytomX Therapeutics from $5.00 to $10.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, November 11th. Barclays upped their price target on CytomX Therapeutics from $3.50 to $6.00 and gave the company an &#34;overweight&#34; rating in a report on Tuesday, October 21st. Wedbush reiterated an &#34;outperform&#34; rating and issued a $6.00 price objective on shares of CytomX Therapeutics in a report on Friday, November 7th. Wall Street Zen lowered CytomX Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, November 8th. Finally, Cantor Fitzgerald began coverage on shares of CytomX Therapeutics in a report on Monday, September 22nd. They set an &#34;overweight&#34; rating and a $6.00 price target on the stock. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $6.67.</p>
<div class="lb-trans"><p>几位分析师对该公司进行了评论。HC Wainwright 在 11 月 11 日的研究报告中将 CytomX Therapeutics 的目标价从 5.00 美元上调至 10.00 美元，并给予该公司 &#34;买入&#34; 评级。Barclays 在 10 月 21 日的报告中将 CytomX Therapeutics 的目标价从 3.50 美元上调至 6.00 美元，并给予该公司 &#34;增持&#34; 评级。Wedbush 在 11 月 7 日的报告中重申了 &#34;跑赢大盘&#34; 评级，并对 CytomX Therapeutics 的股票设定了 6.00 美元的目标价。华尔街 Zen 在 11 月 8 日的研究报告中将 CytomX Therapeutics 的评级从 &#34;持有&#34; 下调至 &#34;卖出&#34;。最后，Cantor Fitzgerald 在 9 月 22 日的报告中开始覆盖 CytomX Therapeutics 的股票。他们对该股票设定了 &#34;增持&#34; 评级和 6.00 美元的目标价。六位股票研究分析师对该股票给予了买入评级，一位分析师给予了持有评级。根据 MarketBeat，该公司的平均评级为 &#34;适度买入&#34;，共识目标价为 6.67 美元。</p>
</div><p><strong>View Our Latest Analysis on CTMX</strong></p>
<div class="lb-trans"><p><strong>查看我们对 CTMX 的最新分析</strong></p>
</div><h2>CytomX Therapeutics Stock Up 5.6%</h2>
<div class="lb-trans"><h2>CytomX Therapeutics 股票上涨 5.6%</h2>
</div><p>NASDAQ CTMX opened at $4.44 on Friday. The company has a 50-day moving average price of $3.89 and a 200-day moving average price of $2.93. CytomX Therapeutics, Inc. has a 52 week low of $0.40 and a 52 week high of $4.62. The firm has a market capitalization of $751.42 million, a P/E ratio of 11.09 and a beta of 2.37.</p>
<div class="lb-trans"><p>NASDAQ CTMX 周五开盘价为 4.44 美元。该公司的 50 日移动平均价格为 3.89 美元，200 日移动平均价格为 2.93 美元。CytomX Therapeutics, Inc. 的 52 周低点为 0.40 美元，52 周高点为 4.62 美元。该公司的市值为 7.5142 亿美元，市盈率为 11.09，贝塔值为 2.37。</p>
</div><p>CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last announced its earnings results on Thursday, November 6th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.05). CytomX Therapeutics had a net margin of 24.66% and a return on equity of 44.49%. The business had revenue of $5.96 million for the quarter, compared to the consensus estimate of $11.50 million. As a group, equities research analysts anticipate that CytomX Therapeutics, Inc. will post -0.05 EPS for the current year.</p>
<div class="lb-trans"><p>CytomX Therapeutics（NASDAQ:CTMX - 获取免费报告）最近于 11 月 6 日公布了其财报。这家生物技术公司报告的每股收益（EPS）为（0.09）美元，低于市场共识预期的（0.04）美元，差距为（0.05）美元。CytomX Therapeutics 的净利润率为 24.66%，股本回报率为 44.49%。该公司在本季度的收入为 596 万美元，而市场共识预期为 1150 万美元。整体来看，股票研究分析师预计 CytomX Therapeutics, Inc. 本年度将发布 -0.05 的每股收益。</p>
</div><h2>About CytomX Therapeutics</h2>
<div class="lb-trans"><h2>关于 CytomX Therapeutics</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.</p>
<div class="lb-trans"><p>CytomX Therapeutics, Inc. 是一家临床阶段的生物制药公司，专注于基于其专有的 Probody® 平台发现和开发下一代治疗药物。该公司设计了在健康组织中保持不活跃但在肿瘤微环境中选择性激活的掩蔽抗体前药。这种方法旨在增强抗体基础疗法的安全性和耐受性，特别是针对免疫肿瘤学通路的疗法。</p>
</div><p>At the core of CytomX's pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.</p>
<div class="lb-trans"><p>CytomX 的管线核心是 Pacmilimab (CX-072)，这是一种抗 PD-L1 Probody 治疗药物，目前正在针对多种实体瘤适应症进行临床评估。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than CytomX Therapeutics</li>
<li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Washington prepares for war</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>The McDonald's Secret</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 CytomX Therapeutics</li>
<li>将你的 &#34;死钱&#34; 转变为每月 306 美元以上（从这个月开始）</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>华盛顿为战争做准备</li>
<li>在 1 月 1 日之前将 1,000 美元投入这只股票 [不是 NVDA]</li>
<li>麦当劳的秘密</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding CTMX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 CTMX 吗？</strong> 访问 HoldingsChannel.com 获取 CytomX Therapeutics, Inc.（NASDAQ:CTMX - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1RNWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=CTMX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CytomX Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 CytomX Therapeutics 吗？</h2>
</div><p>Before you consider CytomX Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 CytomX Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CytomX Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前... 而 CytomX Therapeutics 并不在名单上。</p>
</div><p>While CytomX Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 CytomX Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Inspire Investing LLC 收购了 522,482 股 CytomX 治疗公司 $CTMX